Home >> Expert Review of Molecular Diagnostics, Volume 7, Number 2

Strategies to reduce late-stage drug attrition due to mitochondrial toxicity

Authors: Dykens, James A; Marroquin, Lisa D; Will, Yvonne

Source: Expert Review of Molecular Diagnostics, Volume 7, Number 2, March 2007 , pp. 161-175(15)

Publisher: Expert Reviews

Buy & download fulltext article:

OR

Price: $73.00 plus tax (Refund Policy)

Abstract:

Mitochondrial dysfunction is increasingly implicated in the etiology of drug-induced toxicities and negative side-effect profiles. Early identification of mitochondrial liabilities for new chemical entities is therefore crucial for avoiding late-stage attrition during drug development. Limitations of traditional methods for assessing mitochondrial dysfunction have discouraged routine evaluation of mitochondrial liabilities. To circumvent this bottleneck, a high-throughput screen has been developed that measures oxygen consumption; one of the most informative parameters for the assessment of mitochondrial status. This technique has revealed that some, but not all, members of many major drug classes have mitochondrial liabilities. This dichotomy encourages optimism that efficacy can be disassociated from mitochondrial toxicity, resulting in safer drugs in the future.
More about this publication?
Related content
Marked list

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
^ Back to top
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page